ATE387909T1 - Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren - Google Patents

Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren

Info

Publication number
ATE387909T1
ATE387909T1 AT01948255T AT01948255T ATE387909T1 AT E387909 T1 ATE387909 T1 AT E387909T1 AT 01948255 T AT01948255 T AT 01948255T AT 01948255 T AT01948255 T AT 01948255T AT E387909 T1 ATE387909 T1 AT E387909T1
Authority
AT
Austria
Prior art keywords
methods
kiaa0175
compositions
neoplastic diseases
chemotherapy
Prior art date
Application number
AT01948255T
Other languages
English (en)
Inventor
Bin Wu
Todd Seeley
Lewis Williams
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE387909T1 publication Critical patent/ATE387909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT01948255T 2000-05-31 2001-05-30 Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren ATE387909T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20843500P 2000-05-31 2000-05-31

Publications (1)

Publication Number Publication Date
ATE387909T1 true ATE387909T1 (de) 2008-03-15

Family

ID=22774595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948255T ATE387909T1 (de) 2000-05-31 2001-05-30 Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren

Country Status (10)

Country Link
US (2) US6974867B2 (de)
EP (1) EP1292289B1 (de)
JP (1) JP2003534786A (de)
AT (1) ATE387909T1 (de)
AU (1) AU2001269726A1 (de)
CA (1) CA2410516A1 (de)
DE (1) DE60133104T2 (de)
ES (1) ES2299493T3 (de)
PT (1) PT1292289E (de)
WO (1) WO2001091739A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7879545B2 (en) * 2003-11-05 2011-02-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier
ATE491044T1 (de) * 2004-08-10 2010-12-15 Oncotherapy Science Inc Gene und polypeptide in verbindung mit brustkrebserkrankungen
US20090163406A1 (en) * 2004-09-30 2009-06-25 The Regents Of The University Of California Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
JP2010539890A (ja) * 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ 放射線治療の応答を予測するための遺伝子シグネチャー
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
US8673308B2 (en) * 2011-02-23 2014-03-18 Als Therapy Development Institute Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases
JP6491113B2 (ja) 2013-02-25 2019-03-27 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
NZ731962A (en) 2014-11-21 2022-07-01 Regeneron Pharma Methods and compositions for targeted genetic modification using paired guide rnas
MX2018014172A (es) 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
DE69725878T2 (de) 1996-08-13 2004-07-29 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzungen zur polynukleotidabgabe
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US6087485A (en) * 1998-01-21 2000-07-11 Axys Pharmaceuticals, Inc. Asthma related genes
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
DE60038220T2 (de) 1999-08-27 2009-03-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon

Also Published As

Publication number Publication date
WO2001091739A3 (en) 2003-01-16
EP1292289B1 (de) 2008-03-05
AU2001269726A1 (en) 2001-12-11
WO2001091739A2 (en) 2001-12-06
US20050282766A1 (en) 2005-12-22
DE60133104T2 (de) 2009-03-12
JP2003534786A (ja) 2003-11-25
EP1292289A2 (de) 2003-03-19
PT1292289E (pt) 2008-04-23
ES2299493T3 (es) 2008-06-01
CA2410516A1 (en) 2001-12-06
US20020049180A1 (en) 2002-04-25
US6974867B2 (en) 2005-12-13
DE60133104D1 (de) 2008-04-17

Similar Documents

Publication Publication Date Title
ATE387909T1 (de) Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren
Karlitepe et al. New approaches for cancer immunotherapy
CY1121648T1 (el) ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΠΡΟΣ ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟ ΘΑΝΑΤΟ l(PD-l) ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΡΚΙΝΟΥ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ANTI-PD-1 ΑΝΤΙΣΩΜΑΤΑ ΜΟΝΑ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΑΛΛΕΣ ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΕΣ
CY1106991T1 (el) Αντιπολλαπλασιαστικη δραση ολιγονουκλεοτιδιων πλουσιων σε g και μεθοδος χρησιμοποιησης αυτων για την προσδεση σε νουκλεολινη
BRPI0412637A (pt) anticorpos, método de seleção de um anticorpo de hvegf, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, método de uso do anticorpo e método de tratamento de um mamìfero
SG170080A1 (en) Human monoclonal antibodies to o8e
ATE459648T1 (de) Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
TW200513532A (en) VEGF traps and therapeutic uses thereof
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
CY1111590T1 (el) Αρυλ και ετεροαρυλ ουριας αναστολεις chk1 για χρηση ως ραδιοευαισθοποιητες και χημειοευαισθητοποιητες
RU94045281A (ru) Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
HK1091216A1 (en) Growth factor complexes and modulation of cell migration and growth
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
NO993943D0 (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
MX2021011330A (es) Anticuerpos de claudina-6 y conjugados de fármacos.
DE50009365D1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
Ye et al. Suppression of CD26 inhibits growth and metastasis of pancreatic cancer
He et al. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
AU2002318934A8 (en) Sak: modulation of cellular proliferation for treatment of cancer
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
DE602004032235D1 (de) Dna-vektoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1292289

Country of ref document: EP

REN Ceased due to non-payment of the annual fee